Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models
Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models
复制标题
DOI：
10.1080/02656736.2017.1365953
复制
发表时间：
2018-01-01
影响因子：
3.1
通讯作者：
Pankhurst, Quentin A.
中科院分区：
文献类型：
--
作者：
Southern, Paul;Pankhurst, Quentin A.
我们提供了一个批评什么构成一个合适的剂量限制，在临床和临床前研究中，为了使治疗性热疗的作用下，外部施加的交变磁场的磁性纳米粒子。我们首先从目前批准的MRI对比度增强，前哨淋巴结检测，铁替代疗法和磁热消融领域的磁性纳米粒子的临床剂量的角度来探讨这一点。我们将其与一个简单的分析模型进行比较，该分析模型基于所注射的剂量、注射流体的加热和分散特性以及所施加磁场的强度和频率，对人类和动物可实现的热疗温升进行分析。我们表明，在适当选择的条件下，在临床相关的情况下，治疗温升是可以实现的。我们还表明，在这种情况下，在临床前模型中实现相同的治疗温升可能会更困难。我们评论的影响，以证据为基础的翻译高温为基础的干预措施，从实验室到临床。
We offer a critique of what constitutes a suitable dosage limit, in both clinical and preclinical studies, for interstitially administered magnetic nanoparticles in order to enable therapeutic hyperthermia under the action of an externally applied alternating magnetic field. We approach this first from the perspective of the currently approved clinical dosages of magnetic nanoparticles in the fields of MRI contrast enhancement, sentinel node detection, iron replacement therapy and magnetic thermoablation. We compare this to a simple analytical model of the achievable hyperthermia temperature rise in both humans and animals based on the interstitially administered dose, the heating and dispersion characteristics of the injected fluid, and the strength and frequency of the applied magnetic field. We show that under appropriately chosen conditions a therapeutic temperature rise is achievable in clinically relevant situations. We also show that in such cases it may paradoxically be harder to achieve the same therapeutic temperature rise in a preclinical model. We comment on the implications for the evidence-based translation of hyperthermia based interventions from the laboratory to the clinic.